Clinical Trial Update: Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating cabozantinib in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer | Phase 1 | Status: COMPLETED